Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths

Bell, 2015, Prevalence of incidental prostate cancer: a systematic review of autopsy studies, Int J Cancer, 137, 1749, 10.1002/ijc.29538 Culp, 2020, Recent global patterns in prostate cancer incidence and mortality rates, Eur Urol, 77, 38, 10.1016/j.eururo.2019.08.005 Van Hemelrijck, 2013, Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer Data Base Sweden 2.0, Int J Epidemiol, 42, 956, 10.1093/ije/dys068 Mohler, 2016, Prostate cancer, version 1.2016, J Natl Compr Cancer Netw, 14, 19, 10.6004/jnccn.2016.0004 Van Buuren, 2012 Westerberg, 2021, Simulation model of disease incidence driven by diagnostic activity, Stat Med, 40, 1172, 10.1002/sim.8833 Jonsson, 2011, Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden, Int J Cancer, 129, 1881, 10.1002/ijc.25846 R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. https://www.r-project.org/. Schröder, 2012, Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC), Eur Urol, 62, 745, 10.1016/j.eururo.2012.05.068 Buzzoni, 2015, Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer, Eur Urol, 68, 885, 10.1016/j.eururo.2015.02.042 Stattin, 2014, Prostate cancer mortality in areas with high and low prostate cancer incidence, J Natl Cancer Inst, 106, dju007, 10.1093/jnci/dju007 Stattin, 2017, Association of radical local treatment with mortality in men with very high-risk prostate cancer: a semiecologic, nationwide, population-based study, Eur Urol, 72, 125, 10.1016/j.eururo.2016.07.023 Hamdy, 2016, 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, N Engl J Med, 375, 1415, 10.1056/NEJMoa1606220 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5 Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174 Orrason, 2021, Comparison of relative survival and cause-specific survival in men with prostate cancer according to age and risk category: a nationwide, population-based study, Am J Epidemiol, 190, 2053, 10.1093/aje/kwab146 Helgstrand, 2017, Diagnostic characteristics of lethal prostate cancer, Eur J Cancer, 84, 18, 10.1016/j.ejca.2017.07.007 Schröder, 2014, Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, Lancet, 384, 2027, 10.1016/S0140-6736(14)60525-0 Grönberg, 2015, Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study, Lancet Oncol, 16, 1667, 10.1016/S1470-2045(15)00361-7 Stattin, 2015, Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case–control study, Eur Urol, 68, 207, 10.1016/j.eururo.2015.01.009 Nordstrom, 2021, Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial, Lancet Oncol, 22, 1240, 10.1016/S1470-2045(21)00348-X Tomic, 2015, Capture rate and representativity of the National Prostate Cancer Register of Sweden, Acta Oncol, 54, 158, 10.3109/0284186X.2014.939299 Godtman, 2011, High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm, Scand J Urol Nephrol, 45, 226, 10.3109/00365599.2011.559950 Epstein, 2016, The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system, Am J Surg Pathol, 40, 244, 10.1097/PAS.0000000000000530 Ohmann, 2014, Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories, Scand J Urol, 48, 426, 10.3109/21681805.2014.892150